ArticleGene therapy2016
Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread.
T Shibata et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
26 papers cite it
this papercites it